Acquisition
Scynexis acquires Poxel SA's PXL770
Originated and led the acquisition. Architected a $40M financing strategy that transformed Scynexis into a rare nephrology-focused company, with ADPKD as the lead indication.
A senior advisory practice built around operating judgment, scientific depth, and the discipline of the public markets.
Begin a conversationEllera Partners was founded in 2020 to bring senior pharma operating judgment and capital-markets perspective into a single advisory practice, purpose-built for the decisions that define a product or franchise.
The work draws on more than two decades of experience inside global pharmaceutical companies, top-tier financial institutions, and academic research: commercial due diligence at Allergan, mid- and large-cap biotech equity research at Citigroup, and a Ph.D. in Pharmaceutical Sciences from the University of Toronto.
Originated and led the acquisition. Architected a $40M financing strategy that transformed Scynexis into a rare nephrology-focused company, with ADPKD as the lead indication.
A novel oral carbapenem for the treatment of complicated urinary tract infections.
Led commercial and financial diligence on the ophthalmology portfolio.
Comprehensive pipeline valuation with a retain vs. out-license recommendation across the portfolio.
Led partnership and capital strategy for a privately held company entering pivotal trials.
Structured a spinout, licensing, and funding arrangement for a deprioritized pipeline asset.
Led lifecycle therapeutic indication prioritization to inform pipeline sequencing and capital allocation.